Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

pemigatinib × Sarcoma × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7 Genitourinary 4 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 CNS 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 47 Specimen Handling 46 Magnetic Resonance Spectroscopy 43 Doxorubicin 39 Temozolomide 35 pembrolizumab 34 Radiotherapy 33 Biopsy 31 Radiation 24 Nivolumab 23 fludarabine 22 Irinotecan 19 X-Rays 18 Vincristine 18 Ifosfamide 17 Gemcitabine 17 atezolizumab 16 Surgical Procedures, Operative 16 Blood Specimen Collection 15 fludarabine phosphate 13 Ipilimumab 13 cabozantinib 12 Etoposide 12 Sirolimus 11 Paclitaxel 11 Bevacizumab 11 regorafenib 10 olaparib 10 Trabectedin 10 Sunitinib 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07434843 2026-02-27

PEMIGIST

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡